Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Bitdeer Technologies Group (BTDR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Bitdeer Technologies Group — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Bitdeer Technologies Group trades at $9.02 (market cap $2.36B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 12.5× Bitdeer Technologies Group's market cap. Which is the better fit depends on your goals.
| ALNY | BTDR | |
|---|---|---|
Market Cap | $29.60B | $2.36B |
Sector | Health | Technology |
52-Week High | $491.22 | $25.90 |
52-Week Low | $205.48 | $7.28 |
Enterprise Value | $27.56B | $3.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
BTDR trades at $9.02, up 3.74% in the last session, with a bearish technical signal from moving averages and oscillators. The company reported Q2 2026 revenue of $812 million but a net loss of $229 million, missing EPS estimates for four consecutive quarters. Recent news highlights a $4.7 billion AI data center deal in Norway, expanding beyond Bitcoin mining, though gross margins remain pressured.
Outlook is mixed: strong analyst buy consensus (81.82%) and a $22.43 price target suggest upside, but persistent losses, negative cash flow from operations, and high dependency on volatile crypto markets pose significant risks. Investors should weigh growth potential in AI infrastructure against execution challenges and profitability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Bitdeer Technologies Group
Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.
Read more on BTDR →
